Long-term treatment with alendronate increases the surgical difficulty during simple exodontias – an in vivo observation in Holtzman rats

Head & Face Medicine

Elcio Marcantonio Jr¹  Rosemary Adriana Chierici Marcantonio¹  Luis Carlos Spolidorio²  Alliny de Souza Bastos¹  Nicolau Conte-Neto¹ 

[1] Department of Diagnosis and Surgery, Division of Periodontology, UNESP- Univ. Estadual Paulista, School of Dentistry, Rua Humaitá, 1680, Araraquara, SP, 14801-903, Brazil;School of Dentistry, Department of Physiology and Pathology, Division of Pathology, UNESP - Univ. Estadual Paulista, Rua Humaitá, 1680, Araraquara, SP, 14801-903, Brazil

关键词: Osteonecrosis;    Tooth extraction;    Bisphosphonates;   

Others  :  817717
DOI  :  10.1186/1746-160X-8-20

 received in 2012-04-12, accepted in 2012-07-13,  发布年份 2012

【 摘 要 】

Background

Atraumatic teeth extractions protocols are highly encouraged in patients taking bisphosphonates (Bps) to reduce surgical trauma and, consequently, the risk of jaws osteonecrosis development. In this way, this paper aims to report the findings of increased surgical difficulty during simple exodontias in animals treated with bisphosphonates.

Methods

Sixty male Holtzman rats were randomly distributed into three groups of 20 animals and received daily subcutaneous administration of 1 mg/kg (AL1) or 3 mg/kg (AL3) of alendronate or saline solution (CTL). After 60 days of drug therapy all animals were submitted to first lower molars extractions under general anesthesia. Operatory surgical time and the frequency of teeth fractures were measured as principal outcomes and indicators of surgical difficulty degree.

Results

Animals treated with alendronate (AL1 and AL3) were associated to higher operatory times and increased frequency of teeth fractures compared to match controls.

Conclusions

The bisphosphonate therapy may be associated with an increased surgical difficulty and trauma following simple exodontias protocols, which is considered a critical issue when it comes to osteonecrosis development.

【 授权许可】

   
2012 Conte-Neto et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bruce RA, Frederickson GC, Small GS: Age of patients and morbidity associated with mandibular third molar surgery. J Am Dent Assoc 1980, 101:240-245.
• [2]Malkawi Z, Al-Omiri MK, Khraisat A: Risk indicators of postoperative complications following surgical extraction of lower third molars. Med Princ Pract 2011, 20:321-325.
• [3]Richer E, Lewis MA, Odvina CV, Vazquez MA, Smith BJ, Peterson RD, et al.: Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 2005, 16:1384-1392.
• [4]Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al.: Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009, 67:1904-1913.
• [5]Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S: Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 2009, 15:88-92.
• [6]Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, et al.: Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2008, 75:34-40.
• [7]Ferlito S, Puzzo S, Liardo C: Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 2011, 69:e1-e4.
• [8]Scoletta M, Arduino PG, Pol R, Arata V, Silvestri S, Chiecchio A, et al.: Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. J Oral Maxillofac Surg 2011, 69:456-462.
• [9]Susarla SM, Dodson TB: Risk factors for third molar extraction difficulty. J Oral Maxillofac Surg 2004, 62:1363-1371.
• [10]Yuan LT, Duan DM, Tan L, Wang XJ, Wu LA: Treatment for a complicated crown-root fracture with intentional replantation: a case report with a 3.5-year follow up. Dent Traumatol 2012,  : . Epub ahead of print
• [11]Renton T, Smeeton N, McGurk M: Factors predictive of difficulty of mandibular third molar surgery. Br Dent J 2001, 190:607-610.
• [12]Santamaria J, Arteagoitia I: Radiologic variables of clinical significance in the extraction of impacted mandibular third molars. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 84:469-473.
• [13]Blondeau F, Daniel NG: Extraction of impacted mandibular third molars: postoperative complications and their risk factors. J Can Dent Assoc 2007, 73:325.
• [14]Bouloux GF, Steed MB, Perciaccante VJ: Complications of third molar surgery. Oral Maxillofac Surg Clin North Am 2007, 19:117-128. vii
• [15]Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18:75-85.
• [16]Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al.: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997, 37:285-290.
• [17]Ezra A, Golomb G: Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000, 42:175-195.
• [18]Reid IR: Bisphosphonates. Skeletal Radiol 2007, 36:711-714.
• [19]Hutchinson M, O’Ryan F, Chavez V, Lathon PV, Sanchez G, Hatcher DC, et al.: Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg 2010, 68:2232-2240.
• [20]Adeyemo WL, Ladeinde AL, Ogunlewe MO: Influence of trans-operative complications on socket healing following dental extractions. J Contemp Dent Pract 2007, 8:52-59.
• [21]Birn H: Fibrinolytic activity of alveolar bone in “dry socket”. Acta Odontol Scand 1972, 30:23-32.
• [22]Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al.: Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 2009, 45:843-852.
• [23]Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
• [24]Currey JD, Brear K, Zioupos P: The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 1996, 29:257-260.
• [25]Burr DB, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, et al.: Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003, 33:960-969.
• [26]Allen MR, Burr DB: The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009, 67:61-701.